Overview
- 4 inspections across 4 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2018-04-20.
At a glance
Inspections
4
Sites
4
Observations
0
Career since
May 2017
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Novartis Pharma AG | 20 Apr 2018 | Human Drugs | |
| Hexal Ag | 17 Apr 2018 | Human Drugs | |
| Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC | 12 Oct 2017 | Human Drugs | |
| Boehringer Ingelheim Pharma GmbH and Co. KG | 26 May 2017 | Human Drugs | On file |
Sites inspected
Novartis Pharma AGBasel, Switzerland1 insp.
Hexal AgOberhaching, Germany1 insp.
Wyeth BioPharma Division of Wyeth Pharmaceuticals LLCAndover, United States1 insp.
Boehringer Ingelheim Pharma GmbH and Co. KGBiberach An Der Ris, Germany1 insp.
Co-investigators
Investigators who share inspections with this person.
Stephen D Brown2 shared
Christopher D Downey2 shared
Richard Ledwidge1 shared
Monica M Commerford1 shared
Sean R Marcsisin1 shared
Kathleen R Jones1 shared
Veronica Fuentes1 shared
Anh Lac1 shared
Full investigator report
Get the verbatim findings behind Yanming An's inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site